Is Eagle Pharmaceuticals, Inc. (EGRX) a Buy, Sell, or Hold?
Eagle Pharmaceuticals, Inc.
OTC:EGRX
$0.1214 USD
-$0.55 (-81.88%)
- Volume
- 293
- Average Volume
- 3.88K
- Market Capitalization
- $1.6M
- P/E Ratio
- 0.04
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $3.87
- Year Low
- $0.09
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.70
Industry, Sector & symbol
| Stock Exchange | OTC |
| CEO | Michael Graves |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Current Symbol | EGRX |
| CUSIP | 269796108 |
| CIK | None |
| Web | https://www.eagleus.com |
| Phone | 201 326 5300 |
| Currency | USD |
| Employees | 141 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.29 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.70 |
| Quick Ratio | 1.27 |
| Cash Ratio | 0.50 |
Sales & Book Value
| Annual Sales | $316.61M |
| Price / Sales | 0.01 |
| Cash Flow | 2.38 |
| Price / Cash Flow | 0.05 |
| Price / Book | 0.01 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 6 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $2.73 |
| Trailing P/E Ratio | 0.04 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $35.64M |
| Net Margin | 11.26% |
| Pretax Margin | 19.40% |
| Return on Equity | 17.39% |
| Return on Assets | 8.78% |
Financials Score
| AltmanZ Score | 1.68 |
| Piotroski Score | 4.00 |
| Working Capital | 100.62M |
| Total Assets | 404.82M |
| Ebit | 35.33M |
| Market Cap | 8.82M |
| Total Liabilities | 152.78M |
Poll Results
About Eagle Pharmaceuticals, Inc. (OTC:EGRX) Stock
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (P ... ONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Critical Contrast: Eagle Pharmaceuticals (NASDAQ:EGRX) & Indivior (OTCMKTS:INVVY)
2026-04-17 01:44:50
Eagle Pharmaceuticals (NASDAQ: EGRX - Get Free Report) and Indivior (OTCMKTS:INVVY - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and profitability. Analyst Ratings This is a breakdown of recent recommendations
Frequently Asked Questions
-
What is the current Eagle Pharmaceuticals, Inc. (EGRX) stock price?
-
Eagle Pharmaceuticals, Inc.(OTC:EGRX) stock price is $0.1214 in the last trading session. During the trading session, EGRX stock reached the peak price of $3.87 while $0.085 was the lowest point it dropped to. The percentage change in EGRX stock occurred in the recent session was --81.88% while the dollar amount for the price change in EGRX stock was -$-0.55.
-
EGRX's industry and sector of operation?
-
The OTC listed EGRX is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of EGRX?
-
Valentin R. Curt | Senior Vice President of Clinical Drug Development
Christopher Krawtschuk | Chief Financial Officer and Principal Financial & Accounting Officer
Daniel O'Connor | Executive Vice President, Chief Strategy Officer & Head of Corporate Development
Michael Graves | CEO & Chairman
Debra Hussain | Senior Vice President & Head of Commercial -
How many employees does EGRX have?
-
Number of EGRX employees currently stands at 141. EGRX operates from 50 Tice Boulevard, Woodcliff Lake, NJ 07677, US.
-
Link for EGRX official website?
-
Official Website of EGRX is: https://www.eagleus.com
-
How do I contact EGRX?
-
EGRX could be contacted at phone #201 326 5300 and can also be accessed through its website. EGRX operates from 50 Tice Boulevard, Woodcliff Lake, NJ 07677, US.
-
How many shares of EGRX are traded daily?
-
The average number of EGRX shares traded daily for last 3 months was 3.88K.
-
What is the market cap of EGRX currently?
-
The market value of EGRX currently stands at $1.6M with its latest stock price at $0.1214